Philippe Leboulch - Genetic Mutations

Author Information

Philippe Leboulch is affiliated with the Division of Innovative Therapies at the CEA François Jacob Biology Institute in Fontenay-aux-Roses, France, and the Genetics Division at Brigham & Women's Hospital and Harvard Medical School in Boston, MA, USA. His research focuses on genetic therapies and their application in treating hemoglobinopathies.

Research Contributions

Philippe Leboulch has made significant contributions to the field of genetic therapies, particularly in the area of hemoglobinopathies. His work focuses on lentiviral gene therapy, aiming to develop effective treatments for conditions such as β-thalassemia and sickle cell disease. Notable papers include studies on the long-term outcomes of lentiviral gene therapy for β-hemoglobinopathies, coordinated β-globin expression in gene therapy vectors, and the enhanced transduction of hematopoietic cells with chimeric lentiviral vectors.

Aliases

Philippe Leboulch is also known by the aliases P. Leboulch and P Leboulch.

Publication and Citation Metrics

Metric	Value
Total Citations	14,719
h-index	52
Total Papers	171

Publications:

Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.

DOI: 10.1038/s41591-021-01650-w

Year: 2022

Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia.

DOI: 10.1016/j.ymthe.2021.04.037

Year: 2021

S141 CLINICAL OUTCOMES OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSAEMIA (TDT) FOLLOWING COMPLETION OF THE NORTHSTAR (HGB-204) STUDY

DOI: 10.1097/01.hs9.0000558784.71127.f8

Year: 2019

GENE THERAPY OF THE β-HEMOGLOBINOPATHIES

DOI: 10.1142/9781786346889_0023

Year: 2019

Enhanced Transduction of Macaca fascicularis Hematopoietic Cells with Chimeric Lentiviral Vectors.

DOI: 10.1089/hum.2018.179

Year: 2019

Gene Therapy of the β Hemoglobinopathies: Success and Challenges

DOI: 10.1080/03630269.2020.1715572

Year: 2019

The integrity of the FOG‐2 LXCXE pRb‐binding motif is required for small intestine homeostasis

DOI: 10.1113/EP087369

Year: 2019

Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.

DOI: 10.1016/j.exphem.2018.05.004

Year: 2018

High-level b-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells

DOI:

Year: 2018

UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells

DOI: 10.1016/j.omtm.2018.06.009

Year: 2018

Are Synonymous Codons Truly Silent?

How Do Genetic Mutations Contribute to Heart Disease?

What are Some Common TKIs?

What are Deletions?

What Role Do Genes Play in Brain Development?

How Do We Address Inequality in Access to Genetic Treatments?

What are the Symptoms of Cystic Fibrosis Due to Delta F508 Mutation?

What is Sickle Cell Trait?

How Does the Neutral Theory Affect Our Understanding of Genetic Diversity?

How Do Genetic Mutations Affect Immunotherapy?

Partnered Content Networks

Relevant Topics